🇺🇸 Clindamycin + BPO in United States
10 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 10
Most-reported reactions
- Burning Sensation — 1 report (10%)
- Chemical Burn Of Skin — 1 report (10%)
- Drug Ineffective — 1 report (10%)
- Dry Eye — 1 report (10%)
- Dyspnoea — 1 report (10%)
- Erythema — 1 report (10%)
- Eye Swelling — 1 report (10%)
- Headache — 1 report (10%)
- Inappropriate Schedule Of Product Administration — 1 report (10%)
- Nausea — 1 report (10%)
Other Dermatology approved in United States
Frequently asked questions
Is Clindamycin + BPO approved in United States?
Clindamycin + BPO does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Clindamycin + BPO in United States?
GlaxoSmithKline is the originator. The local marketing authorisation holder may differ — check the official source linked above.